Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Expression of MAC-1 (CD11b) in acute myeloid leukemia (AML) is associated with an unfavorable prognosis.

Graf M, Reif S, Kröll T, Hecht K, Nuessler V, Schmetzer H.

Am J Hematol. 2006 Apr;81(4):227-35.

3.

Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/macrophage colony stimulating factor vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia: final results of a randomized phase III study (06903) of the EORTC Leukemia Cooperative Group.

Zwierzina H, Suciu S, Loeffler-Ragg J, Neuwirtova R, Fenaux P, Beksac M, Harousseau J, Nuessler V, Cermak J, Solbu G, Willemze R, de Witte T, Amadori S; EORTC Leukemia Cooperative Group.

Leukemia. 2005 Nov;19(11):1929-33.

PMID:
16151466
4.

Leukemia-derived dendritic cells can be generated from blood or bone marrow cells from patients with acute myeloid leukaemia: a methodological approach under serum-free culture conditions.

Kufner S, Zitzelsberger H, Kroell T, Pelka-Fleischer R, Salem A, de Valle F, Schweiger C, Nuessler V, Schmid C, Kolb HJ, Schmetzer HM.

Scand J Immunol. 2005 Jul;62(1):86-98.

5.

Serum levels of CD137 ligand and CD178 are prognostic factors for progression of myelodysplastic syndrome.

Salih HR, Nuessler V, Denzlinger C, Starling GC, Kiener PA, Schmetzer HM.

Leuk Lymphoma. 2004 Feb;45(2):301-8.

PMID:
15101715
6.

Low L-selectin (CD62L) expression in acute myeloid leukemia correlates with a bad cytogenetic risk.

Graf M, Reif S, Hecht K, Pelka-Fleischer R, Pfister K, Nuessler V, Schmetzer H.

Eur J Haematol. 2003 Nov;71(5):366-76.

PMID:
14667200
7.

Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer.

Kaufmann AM, Stern PL, Rankin EM, Sommer H, Nuessler V, Schneider A, Adams M, Onon TS, Bauknecht T, Wagner U, Kroon K, Hickling J, Boswell CM, Stacey SN, Kitchener HC, Gillard J, Wanders J, Roberts JS, Zwierzina H.

Clin Cancer Res. 2002 Dec;8(12):3676-85.

8.

Cytoprotective features of selenazofurin in hematopoietic cells.

Pogrebniak A, Hasmann M, Schemainda I, Pelka-Fleischer R, Nuessler V.

Int J Clin Pharmacol Ther. 2002 Aug;40(8):368-75.

PMID:
12467305
9.

Differentiation of promyelocytic leukaemia: alterations in Fas (CD95/Apo-1) and Fas ligand (CD178) expression.

Salih HR, Starling GC, Brandl SF, Pelka-Fleischer R, Haferlach T, Hiddemann W, Kiener PA, Nuessler V.

Br J Haematol. 2002 Apr;117(1):76-85.

PMID:
11918536
10.

Modulation of apoptosis by mitochondrial uncouplers: apoptosis-delaying features despite intrinsic cytotoxicity.

Stoetzer OJ, Pogrebniak A, Pelka-Fleischer R, Hasmann M, Hiddemann W, Nuessler V.

Biochem Pharmacol. 2002 Feb 1;63(3):471-83.

PMID:
11853698
11.

Soluble CD137 (4-1BB) ligand is released following leukocyte activation and is found in sera of patients with hematological malignancies.

Salih HR, Schmetzer HM, Burke C, Starling GC, Dunn R, Pelka-Fleischer R, Nuessler V, Kiener PA.

J Immunol. 2001 Oct 1;167(7):4059-66.

12.

Bcl-2, bax and bcl-xL expression in human sensitive and resistant leukemia cell lines.

Nuessler V, Stötzer O, Gullis E, Pelka-Fleischer R, Pogrebniak A, Gieseler F, Wilmanns W.

Leukemia. 1999 Nov;13(11):1864-72.

PMID:
10557064
13.
14.

Apoptosis research is saving the reputation of chemotherapy

Gieseler F, Nuessler V V.

Leukemia. 1999 Nov;13(11):1853. No abstract available.

PMID:
10557061
15.

Endogenous FLT-3 ligand serum levels are associated with disease stage in patients with myelodysplastic syndromes.

Zwierzina H, Anderson JE, Rollinger-Holzinger I, Torok-Storb B, Nuessler V, Lyman SD.

Leukemia. 1999 Apr;13(4):553-7.

PMID:
10214861
16.

A European perspective on haematopoietic growth factors in haemato-oncology: report of an expert meeting of the EORTC.

Croockewit AJ, Bronchud MH, Aapro MS, Bargetzi MJ, Crown J, Gratwohl A, Lange W, Ludwig H, Martinelli G, Mertelsmann R, Nuessler V, Willemze R, De Witte TJ, Zittoun R, Zwierzina H.

Eur J Cancer. 1997 Oct;33(11):1732-46. Review. No abstract available.

PMID:
9470826
17.

Functional P-gp expression in multiple myeloma patients at primary diagnosis and relapse or progressive disease.

Nuessler V, Gieseler F, Gullis E, Pelka-Fleischer R, Stötzer O, Zwierzina H, Wilmanns W.

Leukemia. 1997 Dec;11 Suppl 5:S10-4.

PMID:
9436932
18.

Endogenous serum thrombopoietin concentrations in patients with myelodysplastic syndromes.

Zwierzina H, Rollinger-Holzinger I, Nuessler V, Herold M, Meng YG.

Leukemia. 1998 Jan;12(1):59-64.

PMID:
9436921
19.

Expression and functional activity of P-glycoprotein in adult acute myelogenous leukemia patients.

Nuessler V, Gullis E, Pelka-Fleischer R, del Valle F, Diem H, Beyerlein S, Zwierzina H, Wilmanns W.

Ann Hematol. 1997 Jul-Aug;75(1-2):17-26.

PMID:
9322679
20.

Effects of progesterone and leukotriene receptor antagonists in experimental models of P-glycoprotein-related resistance.

Nuessler V, Pelka-Fleischer R, Zwierzina H, Wilmanns W, Denzlinger C.

Eur J Med Res. 1997 Apr 21;2(4):159-64.

PMID:
9110922
21.

Phase I and pharmacokinetic study of the P-glycoprotein modulator dexniguldipine-HCL.

Nuessler V, Scheulen ME, Oberneder R, Kriegmair M, Goebel KJ, Rathgeb F, Wurst W, Zech K, Wilmanns W.

Eur J Med Res. 1997 Feb 21;2(2):55-61.

PMID:
9085015
22.

Topoisomerase II activities in AML and their correlation with cellular sensitivity to anthracyclines and epipodophyllotoxines.

Gieseler F, Glasmacher A, Kämpfe D, Wandt H, Nuessler V, Valsamas S, Kunze J, Wilms K.

Leukemia. 1996 Jul;10(7):1177-80.

PMID:
8683999
23.

Topoisomerase II activities in AML blasts and their correlation with cellular sensitivity to anthracyclines and epipodophyllotoxines.

Gieseler F, Glasmacher A, Kämpfe D, Wandt H, Nuessler V, Valsamas S, Kunze J, Wilms K.

Leukemia. 1996 Jul;10 Suppl 3:S46-S49.

PMID:
8656700

Supplemental Content

Loading ...
Support Center